{"prompt": "['MEIRAGTx', 'Gene Therapy for Achromatopsia (CNGA3)', 'section 5.4.2.1 for details) to allow direct comparison of the data sets. These assessments will be', 'scheduled over a period of a day for visits at day 1, day 3, day 7, week 2, week 4 and week 6 after', 'surgery, and up to 4 days for baseline examinations, and 3 months, 6 months following ATIMP', 'administration. For day 1 and 3 refraction cannot reliably be measured. Therefore, the most recent', 'refraction measurement will be used.', 'All participants will need to be able to perform reliable visual acuity testing and SD-OCT imaging, which', 'are the principal clinical assessments both for safety and efficacy. Other clinical assessments will be', 'undertaken as appropriate for the ability of individual participants, since there is wide variation in the', 'abilities of individual children to perform such tests reliably; the evaluations for individuals may be', 'restricted to those tests that they are able to perform reliably.', 'Additional assessments may be performed if considered appropriate for the management of any', 'unexpected adverse effects. These may be submitted as urgent safety measures and protocol', 'amendments performed where required. Conversely, tests that cannot be reliably performed by a', 'particular participant may be discontinued for that participant. This is not anticipated for the key', 'clinical assessments such as visual acuity test or SD-OCT imaging because participants who are unable', 'to perform such tests will be excluded from the study at the screening phase. Evaluation of safety and', 'efficacy will also be performed on an individual participant basis. We do not anticipate that any', 'discontinuation will affect significantly the overall quality of the safety and efficacy evaluation.', '5.4.2.4 Laboratory Procedures', 'Blood serum will be processed, to investigate any immune responses to the ATIMP:', '1. anti-AAV8 neutralising antibodies', '2. anti-AAV8 antibodies using an ELISA', 'Blood serum, saliva and lacrimal fluid will be processed in the UCL Institute of Ophthalmology to assess', 'dissemination of ATIMP after delivery, where the number of rAAV vector genome copies will be', 'measured using a polymerase chain reaction (PCR) approach.', 'Whole blood will be processed at the National Genetics Reference Laboratory in the UK, or a CLIA-', 'accredited molecular diagnostic laboratory in the US, for CNGA3 mutation screening. Haematology', 'and biochemistry samples and screen will be carried out at the Trust associated laboratories, or an', 'accredited laboratory in the US.', 'Biochemistry and haematology parameters to be analysed are as per the table below:', 'Haematology', 'Biochemistry', 'Haemoglobin', 'Sodium', 'Haematocrit', 'Potassium', 'Erythrocytes', 'Chloride', 'Mean Corpuscular Volume', 'Bilirubin', 'Mean Corpuscular Haemoglobin', 'Alkaline Phosphatase', 'Platelet', 'Aspartate Aminotransferase', 'CNGA3 MGT012 Protocol version 6.0 16Apr2021', 'Page 40 of 68']['MEIRAGTx', 'Gene Therapy for Achromatopsia (CNGA3)', 'Leukocytes', 'Alanine Aminotransferase', 'Absolute Neutrophils', 'Lactate Dehydrogenase', 'Absolute Lymphocytes', 'Gamma Glutamyl Transferase', 'Absolute Neutrophils', 'Protein', 'Absolute Eosinophils', 'Albumin', 'Absolute Basophils', 'Calcium', 'Magnesium', 'Phosphate', 'Urea', 'Urate', 'Creatinine', 'Glucose', '5.4.3 Dispensing', '5.4.3.1 Receipt and Storage of the Advanced Therapy Investigational Medicinal Product', 'The batch of ATIMP will be stored at either the MeiraGTx II Ltd Manufacturing Facility (MeiraGTx MF),', 'or other approved storage facility (details of storage will be specified in the ATIMP Management Plan).', 'The product, which is stable at <-70\u00b0 Celsius, will be stored at -70\u00b0 Celsius or below in secure', 'temperature controlled and monitored -80\u00b0 Celsius freezers. No further manufacturing or testing will', 'take place at the MeiraGTx MF. Shipping of ATIMP will be on dry ice, accompanied by a temperature-', 'monitoring device.', 'The ATIMP vector will be dispensed on the same day of administration according to study specific', 'working instructions, with a 1-hour window for administration after ATIMP has thawed at room', 'temperature.', '5.4.4 Dosages', '5.4.4.1 Dosages and dosage modifications', 'Trial participants will receive a single dose of ATIMP within the range proven to be safe in the', 'preclinical animal studies. These are anticipated to be as described below:', '1) low dose', '2)', 'intermediate dose', '3) high dose', 'In order to explore optimal dosing within safe limits, additional doses may be administered in order', 'to maximise therapeutic effect, whilst maintaining the safety profile of the product. Any dose that', 'differs from those described above will not exceed the highest titre of', '.', 'The Chief', 'CNGA3 MGT012 Protocol version 6.0 16Apr2021', 'Page 41 of 68']\n\n###\n\n", "completion": "END"}